Clinical Trials Logo

Clinical Trial Summary

To assess the safety and biological efficacy of prophylactically administered donor-derived multi-infection specific cytotoxic T lymphocytes (CTLs) (targeting cytomegalovirus (CMV), Adenovirus (Adv), Epstein Barr virus (EBV), Varicella-Zoster virus (VZV), Influenza (Flu), BK virus (BKV), and Aspergillus (Asp)) combined with early immunisation with Influenza and VZV vaccines for the prevention of viral and fungal infection following allogeneic blood or marrow stem cell transplantation.


Clinical Trial Description

The study will analyse the safety and biological efficacy of administering the investigational products (donor-derived T cells stimulated with viral and fungal antigen expressing DC combined with Flu and VZV immunisation), for the prophylaxis of viral and fungal reactivation and/or infection following allogeneic blood or marrow transplantation. The cells will be given prophylactically a minimum of 28 days after transplantation followed by administration of the Flu and VZV vaccines 24 to 72 hours later. The AIMS are to study the safety of combining CTL infusions and vaccination as well as their effect on reconstitution of infection-specific immunity, viral and Aspergillus reactivation and infection rates after transplantation, viral load, and use of antiviral and antifungal pharmacotherapy for specific infections. The investigators will also evaluate the safety of infusions and vaccinations with respect to the development adverse events within the first 12 months post transplant. ;


Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT02843321
Study type Interventional
Source University of Sydney
Contact
Status Active, not recruiting
Phase Phase 1
Start date August 2012
Completion date December 2017

See also
  Status Clinical Trial Phase
Terminated NCT02514733 - Association of Donor Age With Recipient Outcomes in Kidney Transplant
Completed NCT02014103 - Conversion From Brand to Generic Tacrolimus in High Risk Transplant Recipients Phase 4
Completed NCT02068872 - Gastric Sleeve Pilot Study in Morbidly Obese Undergoing Liver Transplantation Phase 1
Completed NCT02207322 - Supportive Care Intervention In Patients Hospitalized For Hematopoietic Stem Cell Transplantation (Shield) N/A
Completed NCT02800811 - Safety, Tolerability, PK, PD, and Immunogenicity of Single and Multiple Ascending Intravenous Doses of FR104 Phase 1